303 results on '"Deambrogi, Clara"'
Search Results
2. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
3. Diffuse large B-cell lymphoma genotyping on the liquid biopsy
4. Supplementary Tables S1-S4 from The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
5. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
6. Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients
7. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
8. Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib
9. Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia
10. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
11. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
12. Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironment
13. CLL-358: Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and Bypass Signaling via the MAPK Pathway
14. Poster: CLL-358: Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and Bypass Signaling via the MAPK Pathway
15. Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies.
16. Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Α Training/Validation Study
17. Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironment.
18. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
19. Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics
20. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
21. BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance
22. Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia
23. An update on: molecular genetics of high-risk chronic lymphocytic leukemia
24. XPO1 Mutations May Identify Binet Α Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment
25. Genome wide DNA-profiling of HIV-related B-cell lymphomas
26. 14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia
27. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
28. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome
29. Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait
30. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders
31. JAK2V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders
32. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders
33. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas
34. Molecular histogenesis of plasmablastic lymphoma of the oral cavity
35. Molecular histogenesis of posttransplantation lymphoproliferative disorders
36. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma
37. Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring
38. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia
39. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
40. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
41. Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia
42. A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression
43. Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation
44. An update on: molecular genetics of high-risk chronic lymphocytic leukemia.
45. Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
46. Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy
47. Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up
48. Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia
49. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma
50. Clinical impact of small subclones harboring NOTCH1 , SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.